Damora Therapeutics (DMRA) Total Current Liabilities (2019 - 2026)

Damora Therapeutics has reported Total Current Liabilities for 8 years, with the latest figure at $23.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 1388.25% year-over-year to $23.8 million; the trailing twelve-month figure through Mar 2026 stood at $23.8 million (up 1388.25% YoY), and the FY2025 full-year result was $20.1 million, up 1575.0% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $23.8 million, up from $20.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $23.8 million in Q1 2026, with the low at $1.2 million in Q4 2024.
• Historically, Total Current Liabilities has averaged $8.5 million across 5 years, with a median of $7.2 million in 2022.
• Annual changes were most pronounced in 2024 — Total Current Liabilities tumbled 80.63% — and 2025, when it soared 1575.0%.
• Damora Therapeutics' Total Current Liabilities stood at $11.1 million in 2022, then slumped by 47.78% to $5.8 million in 2023, then sank by 79.31% to $1.2 million in 2024, then soared by 1575.0% to $20.1 million in 2025, then advanced by 18.47% to $23.8 million in 2026.
• The last three Total Current Liabilities figures came in at $23.8 million (Q1 2026), $20.1 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.